Morphinan Alkaloid Biosynthesis Using C-14 Hydroxylase Host Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing manufacturing methods for benzylisoquinoline alkaloids and their derivatives suffer from low yields and produce undesirable by-products, with no commercially viable biosynthetic methods available.
Innovation Solution
The method involves engineering host cells to express heterologous enzymes, particularly cytochrome P450 proteins with C-14-hydroxylase activity, along with cytochrome P450 reductase, to convert precursor morphinan alkaloids with a free hydrogen at carbon C-14 into products with a hydroxyl group, using simple starting materials like sugar and L-tyrosine, and optimizing enzyme expression to reduce by-products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing manufacturing methods are used for benzylisoquinoline alkaloids, then production can be achieved, but yields are low and undesirable by-products are generated
Solution Approach 1:
The patent extracts and removes the harmful by-product formation pathway by using engineered host cells with specific heterologous enzymes that selectively catalyze the desired reaction pathway, preventing the formation of undesirable by-products while maintaining productivity
Solution Approach 2:
The patent changes the biochemical parameters of the production system by introducing heterologous enzymes with specific catalytic activities (C-14-hydroxylase, formaldehyde dehydrogenase, alcohol dehydrogenase) that alter the reaction pathway to favor desired products and minimize by-products
2Productivity
If existing manufacturing methods are used for benzylisoquinoline alkaloids, then production can be achieved, but yields are low
Solution Approach 1:
The patent segments the complex biosynthetic pathway into discrete enzymatic steps, each catalyzed by a specific heterologous enzyme that can be independently expressed and optimized in the engineered host cell, thereby improving yield while managing complexity
Solution Approach 2:
The patent creates a universal engineered host cell platform that can produce diverse benzylisoquinoline alkaloids by expressing different combinations of heterologous enzymes, allowing the same system to be adapted for multiple product applications
3Productivity
If heterologous enzymes are expressed in engineered host cells to increase production, then diverse alkaloid products are produced in higher quantities, but the device complexity increases
Solution Approach 1:
The patent performs preliminary engineering of the host cell by pre-installing the necessary heterologous enzymes and biosynthetic pathways, so that once engineered, the cell can autonomously produce high quantities of diverse alkaloids without requiring complex external control systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the production of diverse benzylisoquinoline alkaloids, with engineered host cells producing at least 1.5 to 50% more of the desired products compared to non-engineered cells, while minimizing by-products such as formaldehyde, tyrosol, and phenylethanol.
Implementation Method 1
one or more enzymes providing C-14-hydroxylase activity in an engineered host cell
Implementation Method 2
the one or more enzymes providing C-14-hydroxylase activity is a cytochrome P450 protein
Implementation Method 3
overexpression of formaldehyde dehydrogenases
Implementation Method 4
overexpression of alcohol dehydrogenases
Data Source
AI summary
Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and/or buprenorphine.